Article
Hematology
Emmanuel Bachy, Kerry J. Savage, Huiqiang Huang, Yok-Lam Kwong, Giuseppe Gritti, Qingyuan Zhang, Anna Marina Liberati, Junning Cao, Haiyan Yang, Siguo Hao, Jianda Hu, Keshu Zhou, Mario Petrini, Filomena Russo, Huilai Zhang, Wei Sang, Jie Ji, Andres Jose Maria Ferreri, Gandhi Laurent Damaj, Hui Liu, Wei Zhang, Xiaoyan Ke, Chiara Ghiggi, Sha Huang, Xiaotong Li, Hui Yao, Jason Paik, William Noveotny, Wenxiao Zhou, Hongji Zhu, Pier Luigi Zinzani
Summary: This study evaluated the efficacy and safety of the programmed cell death protein 1 inhibitor tislelizumab in patients with relapsed/refractory mature T-and natural killer-cell neoplasms. The results showed that tislelizumab had modest efficacy and good safety in these patients.
Article
Hematology
Sara Beygi, George E. Duran, Sebastian Fernandez-Pol, Alain H. Rook, Youn H. Kim, Michael S. Khodadoust
Summary: Resistance to mogamulizumab in mycosis fungoides and Sezary syndrome is often associated with loss of CCR4 expression and emergence of CCR4 genomic alterations. This finding has significant implications for the management and monitoring of patients receiving mogamulizumab and the development of future CCR4-directed therapies.
Article
Oncology
Christopher N. Nguyen, Swaminathan P. Iyer, Madeleine Duvic, Prajak J. Barde, Ajit Nair, Kasi Viswanath Routhu, Auris O. Huen
Summary: Mycosis fungoides (MF) and Sezary Syndrome (SS) are common subtypes of cutaneous T cell lymphomas (CTCL). Advanced-stage MF/SS have poor prognoses and may not respond to multiple systemic treatments. In this case, Tenalisib, an inhibitor of the phosphatidylinositol 3-kinase (PI3K) pathway, was used in combination with Romidepsin to achieve complete remission in a relapsed/refractory SS patient, and long-term remission was maintained with Tenalisib monotherapy.
INVESTIGATIONAL NEW DRUGS
(2023)
Article
Hematology
Jan P. Nicolay, Susanne Melchers, Jana D. Albrecht, Chalid Assaf, Edgar Dippel, Rudolf Stadler, Ulrike Wehkamp, Marion Wobser, Jing Zhao, Ina Burghaus, Sven Schneider, Karsten Guelow, Sergij Goerdt, Christian M. Schuerch, Jochen S. Utikal, Peter H. Krammer
Summary: The study suggests that dimethyl fumarate (DMF) has the potential to block NF-kappa B and kill CTCL cells, making it an effective and well-tolerated therapeutic option for patients with CTCL.
Article
Medicine, General & Internal
Alessandro Pileri, Martina Cavicchi, Clara Bertuzzi, Simona Righi, Corrado Zengarini, Elena Sabattini, Giovanna Roncador, Claudio Agostinelli
Summary: TOX may serve as a diagnostic marker for distinguishing early CTCL stages from IBD, but not as a prognostic marker.
Article
Biochemical Research Methods
Corin F. Otesteanu, Martina Ugrinic, Gregor Holzner, Yun-Tsan Chang, Christina Fassnacht, Emmanuella Guenova, Stavros Stavrakis, Andrew DeMello, Manfred Claassen
Summary: iCellCnn is a deep learning approach for blood diagnostics that achieves accurate classification of specific diseases like SS based on bright-field IFC images. This weakly supervised method is expected to expand the diagnostic potential of IFC by providing automatic data-driven diagnosis for diseases with unknown morphological manifestations.
CELL REPORTS METHODS
(2021)
Article
Oncology
Alyxzandria M. Gaydosik, Connor J. Stonesifer, Alexandra E. Khaleel, Larisa J. Geskin, Patrizia Fuschiotti
Summary: This study used single-cell methods to investigate the transcriptional profiles of malignant T-cell clones and reactive T lymphocytes in mycosis fungoides/Sezary syndrome patient samples. The study found that there are several expanded clonotypes in the skin and blood of individual patients, as well as upregulation of common pathways associated with cancer cell metabolism, cell-cycle regulation, de novo nucleotide biosynthesis, and invasion. These findings provide new insights into the pathogenesis of mycosis fungoides/Sezary syndrome and potential targets for personalized therapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Hematology
Joonhee Park, Jay Daniels, Tim Wartewig, Kimberly G. Ringbloom, Maria Estela Martinez-Escala, Sara Choi, Jane J. Thomas, Peter G. Doukas, Jingyi Yang, Caroline Snowden, Calvin Law, Yujin Lee, Katie Lee, Yancong Zhang, Carly Conran, Kyle Tegtmeyer, Samuel H. Mo, David R. Pease, Balaji Jothishankar, Pui-Yan Kwok, Farah R. Abdulla, Barbara Pro, Abner Louissaint, Titus J. Boggon, Jeffrey Sosman, Joan Guitart, Deepak Rao, Juergen Ruland, Jaehyuk Choi
Summary: The study identified 86 putative driver genes in CTCL, including 19 genes not previously implicated in the disease and two mutations never described in any cancer. Functional assays revealed that these mutations enhance T-cell receptor-dependent proliferation, highlighting their importance in lymphomagenesis. Investigations into genetic causes of CTCL heterogeneity found that while there are broad similarities across disease stages, there are significantly more structural variants in leukemic disease, leading to highly recurrent deletions of putative tumor suppressors.
Article
Dermatology
Janika Gosmann, Rudolf Stadler, Koen D. Quint, Ralf Gutzmer, Maarten H. Vermeer
Summary: This study aimed to report on the efficacy, adverse events, and therapy regimens of PEG-IFN alpha in cutaneous T-cell lymphoma. Results showed that PEG-IFN alpha, especially in combination with skin-directed therapies, is an effective treatment option for cutaneous T-cell lymphoma in clinical practice.
ACTA DERMATO-VENEREOLOGICA
(2023)
Article
Dermatology
Janika Gosmann, Annette Bielefeld, Franz-Josef Schmitz, Katrin Schaper-Gerhardt, Ralf Gutzmer, Rudolf Stadler
Summary: This study investigated the effect of Mogamulizumab on TC cells and aberrant T cell population in CTCL patients. The results showed a reduction in abnormal T cell population and normal TC cells after the administration of Mogamulizumab. However, further studies are needed to determine the correlation between TCP and the efficacy of Mogamulizumab.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2023)
Article
Oncology
Delice Kayishunge, Sophia Ly, Joseph Su, Henry K. Wong
Summary: This article presents a demographic and epidemiological analysis of CTCL patients in Arkansas and nationwide. The study found that CTCL primarily affects males, especially young black males. Additionally, the study identified certain geographic and environmental factors associated with CTCL.
Review
Cell Biology
Oleg E. Akilov
Summary: This review analyzes the current state of diagnostic, prognostic, and disease state-monitoring biomarkers of extracorporeal photopheresis (ECP), and outlines the future direction of ECP biomarker discovery. It is of importance to researchers and clinicians seeking to optimize ECP therapy for cutaneous T-cell lymphoma.
Article
Cell Biology
Gabriele Roccuzzo, Silvia Giordano, Gianluca Avallone, Marco Rubatto, Silvia Canonico, Ada Funaro, Erika Ortolan, Rebecca Senetta, Paolo Fava, Maria Teresa Fierro, Simone Ribero, Pietro Quaglino
Summary: In this retrospective analysis, the characteristic of erythroderma in Sezary syndrome was found to be associated with disease outcome. A new prognostic classification was proposed based on this finding.
Review
Cell Biology
Amy Xiao, Oleg E. Akilov
Summary: The loss of CD47 on aging cells signals macrophages to eliminate the target. CD47 acts as a "do-not-eat-me" sign that prevents macrophagal phagocytosis by interacting with its ligand SIRP alpha. Malignant lymphocytes highly express CD47, making them ideal candidates for targeted anti-CD47 therapies. There are various types of anti-CD47-SIRP alpha therapeutic molecules, including monoclonal antibodies, bioengineered proteins, miRNAs, and bispecific antibodies. Blocking the CD47-SIRP alpha axis in combination with targeting secondary tumor microenvironment (TME) may enhance the effectiveness of current immunotherapeutic approaches.
Article
Dermatology
Fawaz Alenezi, Celine Girard, Didier Bessis, Bernard Guillot, Aurelie Du-Thanh, Olivier Dereure
Summary: This study evaluated the benefit/risk ratio of low-dose methotrexate in mycosis fungoides and Sezary syndrome patients with skin lesions. Results showed similar response rates in both types of disease, with a considerable proportion of responders experiencing relapse. Most patients discontinued methotrexate due to treatment failure or toxicity issues.
ACTA DERMATO-VENEREOLOGICA
(2021)
Article
Oncology
Domenico Viola, Ada Dona, Enrico Caserta, Estelle Troadec, Francesca Besi, Tinisha McDonald, Lucy Ghoda, Emine Gulsen Gunes, James F. Sanchez, Jihane Khalife, Marianna Martella, Chatchada Karanes, Myo Htut, Xiuli Wang, Michael Rosenzweig, Arnab Chowdhury, Douglas Sborov, Rodney R. Miles, Paul J. Yazaki, Todd Ebner, Craig C. Hofmeister, Stephen J. Forman, Steven T. Rosen, Guido Marcucci, John Shively, Jonathan J. Keats, Amrita Krishnan, Flavia Pichiorri
Summary: Despite the reduction of NK cells during Dara therapy, they play a pivotal role in the anti-MM activity of Dara. Targeting CD38+ NK cells by Dara also promotes monocyte activation and enhances anti-MM phagocytosis activity. In MM patients who discontinued Dara therapy, targetable unmutated surface CD38 expression is maintained on MM cells, while effector cells with impaired cellular immune function remain.
Article
Medicine, Research & Experimental
Hadas Lewinsky, Emine G. Gunes, Keren David, Lihi Radomir, Matthias P. Kramer, Bianca Pellegrino, Michal Perpinial, Jing Chen, Ting-fang He, Anthony G. Mansour, Kun-Yu Teng, Supriyo Bhattacharya, Enrico Caserta, Estelle Troadec, Peter Lee, Mingye Feng, Jonathan Keats, Amrita Krishnan, Michael Rosenzweig, Jianhua Yu, Michael A. Caligiuri, Yosef Cohen, Olga Shevetz, Shirly Becker-Herman, Flavia Pichiorri, Steven Rosen, Idit Shachar
Summary: Multiple myeloma (MM) is an incurable disease that requires aggressive treatment with significant side effects, and CD84 may serve as a novel therapeutic target in MM by regulating immune cell function to suppress tumor growth. Research has found that MM cells express low levels of CD84, but secrete MIF to induce CD84 expression in the microenvironment, leading to suppression of T cell function through upregulation of MDSCs.
Article
Oncology
Jayeeta Ghose, Ada Dona, Mariam Murtadha, Emine Gulsen Gunes, Enrico Caserta, Ji Young Yoo, Luke Russell, Alena Cristina Jaime-Ramirez, Benjamin G. Barwick, Vikas A. Gupta, James F. Sanchez, Douglas W. Sborov, Steven T. Rosen, Amrita Krishnan, Lawrence H. Boise, Balveen Kaur, Craig C. Hofmeister, Flavia Pichiorri
Summary: Research suggests that oncolytic herpes simplex virus 1 (oHSV-1) may be a potential novel treatment option for multiple myeloma (MM), inducing cell apoptosis to reduce tumor volume. HVEM functions as a critical receptor for infection and targeting.
MOLECULAR THERAPY-ONCOLYTICS
(2021)
Article
Oncology
Ralf Buettner, Le Xuan Truong Nguyen, Corey Morales, Min-Hsuan Chen, Xiwei Wu, Lisa S. Chen, Dinh Hoa Hoang, Servando Hernandez Vargas, Vinod Pullarkat, Varsha Gandhi, Guido Marcucci, Steven T. Rosen
Summary: The combination of 8-Cl-Ado and VEN synergistically inhibits the in vitro growth of AML cells and prolongs survival in a mouse model, possibly by targeting FAO and OXPHOS pathways. This combination represents a promising therapeutic regimen for AML treatment.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Xochiquetzal U. Martinez, Arnab Chowdhury, Tracey Stiller, Joycelynne Palmer, Matthew Loscalzo, Estella Barrios, Farah R. Abdulla, Jasmine Zain, Steven T. Rosen, Christiane Querfeld
Summary: This study found that the impairment of quality of life in cutaneous lymphoma patients correlates with gender, age, race/ethnicity, and stage of mycosis fungoides/Sezary syndrome. While Sezary syndrome patients experience the most negative impact on quality of life, other sub-types of cutaneous lymphomas also affect quality of life and lead to psychosocial distress. The findings highlight the importance of assessing quality of life in all cutaneous lymphoma patients and further exploring disparities across demographic groups.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Xu Cao, Bolei Li, Jing Chen, Jessica Dang, Siqi Chen, E. Gulsen Gunes, Bo Xu, Lei Tian, Sabina Muend, Mustafa Raoof, Christiane Querfeld, Jianhua Yu, Steven T. Rosen, Yingyu Wang, Mingye Feng
Summary: The study found that blocking CD47 and using cabazitaxel can significantly promote the programmed cell removal of TNBC cells, inhibiting tumor development and metastasis, providing a promising new strategy for TNBC treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Dermatology
N. A. Trum, J. Zain, X. U. Martinez, V Parekh, M. Afkhami, F. Abdulla, K. R. Carson, S. T. Rosen, C. L. Bennett, C. Querfeld
Summary: MAR incidence is higher in CTCL patients than previously reported. Diagnosis and treatment of MAR should be emphasized to improve outcomes.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
L. Moyal, C. Arkin, B. Gorovitz-Haris, C. Querfeld, S. Rosen, J. Knaneh, I. Amitay-Laish, H. Prag-Naveh, J. Jacob-Hirsch, E. Hodak
Summary: This study found that MF-derived exosomes are enriched with miR-155 and miR-1246 microRNAs, with miR-155 having a migratory effect on target cells. Plasma levels of cfmiR-1246 were significantly highest in plaque/tumour MF, followed by patch MF, while cfmiR-155 was only upregulated in plaque/tumour MF. Exosomes from MF, but not controls, increased cell migration, suggesting their potential as biomarkers for tumour burden.
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Review
Oncology
Li Du, Wei Liu, Steven T. Rosen
Summary: This review focuses on the role of SUMOylation in tumorigenesis and cancer-related processes such as EMT, metastasis, therapy resistance, and antitumor immune response. Pharmaceutical inhibition of SUMOylation has shown promising potential in improving the outcomes of existing chemo and immune therapies.
CURRENT OPINION IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Xu Hannah Zhang, Chih-Hong Chen, Hongzhi Li, Jack Hsiang, Xiwei Wu, Weidong Hu, David Horne, Sangkil Nam, Jack Shively, Steven T. Rosen
Summary: This study identifies a lipid-binding-domain in p38 gamma MAPK and demonstrates the selective cytotoxicity of inhibitor CSH71 against CTCL Hut78 cells while sparing healthy cells. Targeting the lipid-binding domain of p38 gamma may have significant clinical implications for T lymphoma treatment.
Article
Biotechnology & Applied Microbiology
Li Du, Wei Liu, Flavia Pichiorri, Steven T. Rosen
Summary: This study identified SUMOylation as a potential mechanism regulating lenalidomide resistance in multiple myeloma. Inhibition of SUMOylation can enhance sensitivity to lenalidomide by downregulating IRF4 expression.
CANCER GENE THERAPY
(2023)
Article
Dermatology
Zhen Han, Renee J. Estephan, Xiwei Wu, Chingyu Su, Yate-Ching Yuan, Hanjun Qin, Sung Hee Kil, Corey Morales, Daniel Schmolze, James F. Sanchez, Lei Tian, Jianhua Yu, Marcin Kortylewski, Steven T. Rosen, Christiane Querfeld
Summary: Cutaneous T cell lymphoma (CTCL) is a malignant tumor characterized by chronic inflammation. This study found that miR-155-5p, miR-130b-3p, and miR-21-3p positively correlated with immune checkpoint gene expression in CTCL and were enriched in the IL-6/Jak/signal transducer and activator of transcription signaling pathway.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Review
Biotechnology & Applied Microbiology
Thuy Phan, Xu Hannah Zhang, Steven Rosen, Laleh G. Melstrom
Summary: Gastrointestinal cancers are a major cause of cancer-related morbidity and mortality worldwide. The p38 signaling pathway, particularly p38 gamma, plays a crucial role in cancer development and metastasis. This article provides an overview of p38 and p38 gamma in gastrointestinal cancers, as well as discusses the potential of targeting p38 gamma as a therapy.
CANCER GENE THERAPY
(2023)
Article
Dermatology
Zhen Han, Xiwei Wu, Hanjun Qin, Yate-Ching Yuan, Jasmine Zain, D. Lynne Smith, Oleg E. Akilov, Steven T. Rosen, Mingye Feng, Christiane Querfeld
Summary: This study investigated the effects of CD47 and PD-L1 immune checkpoint blockades on cutaneous T-cell lymphoma (CTCL). The results showed that dual targeting of CD47 and PD-L1 enhanced immune activity and suppressed tumor growth.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Melissa Cheng, Jasmine Zain, Steven T. Rosen, Christiane Querfeld
Summary: This review discusses the recent advancements in biological and novel therapeutics for the management of CTCL. Mogamulizumab and brentuximab vedotin have been approved for CTCL treatment, providing valuable options for patients. Other therapies such as immune checkpoint inhibitors, miRNA inhibitors, and peptide inhibitors show promising results in clinical trials. However, further studies are needed to determine the long-term effectiveness of these treatments.
EXPERT OPINION ON EMERGING DRUGS
(2022)